Eli Lilly & Co.'s Cyramza met its primary endpoint in a phase 3 trial involving patients with a certain kind of bladder cancer.
The drug, in combination with docetaxel, showed that urothelial carcinoma patients whose disease progressed on or after platinum-based chemotherapy achieved superior progression-free survival when compared to chemotherapy.
Although the primary endpoint has been met, Lilly anticipates that overall survival results are likely to be required for global regulatory submissions.
Final overall survival results are expected in mid-2018.
Cyramza is already approved for certain types of cancer, including metastatic non-small cell lung cancer in combination with docetaxel.